![]()
43
| 2 | 2009
Klinisk Biokemi i Norden
tumour marker elevation. Ann Rheum Dis
2007;66:980.
[11] Duraker N, Hot S, Polat Y, Hobek A, Gencler
N, Urhan N. CEA, CA 19-9, and CA 125
in the differential diagnosis of benign and
malignant pancreatic diseases with or wit-
hout jaundice. J Surg Oncol 2007;95:142–7.
[12] Kodama T, Satoh H, Ishikawa H, Ohtsuka
M. Serum levels of CA19-9 in patients with
nonmalignant respiratory diseases. J Clin
Lab Anal 2007;21:103–6.
[13] Steinberg W. The clinical utility of the CA
19-9 tumor-associated antigen. Am J Gast-
roenterol 1990;85:350–5.
[14] Glenn J, SteinbergW, Kurtzman S, Stein-
berg S, SindelarW. Evaluation of the utility
of a radioimmunoassay for serum CA 19-9
levels in patients before and after treatment
of carcinoma of the pancreas. J Clin Oncol
1988;6:462–8.
[15] Lundin J, Roberts P, Kuusela P, Haglund C.
The prognostic value of preoperative serum
levels of CA 19-9 and CEA in patients with
pancreatic cancer. Br J Cancer 1994;69:515–9.
[16] Boeck S, Stieber P, Holdenrieder S, Wilkow-
ski R, Heinemann V. Prognostic and thera-
peutic significance of carbohydrate antigen
19-9 as tumor marker in patients with pan-
creatic cancer. Oncology 2006;70:255–64.
[17] Safi F, Schlosser W, Kolb G, Beger H. Diag-
nostic value of CA 19-9 in patients with
pancreatic cancer and nonspecific gastro-
intestinal symptoms. J Gastrointest Surg
1997;1:106–12.
[18] Maisey N, Norman A, Hill A, Massey A,
Oates J, Cunningham D. CA19-9 as a prog-
nostic factor in inoperable pancreatic can-
cer: the implication for clinical trials. Br J
Cancer 2005;93:740–3.
[19] Stemmler J, Stieber P, Szymala A, et al. Are
serial CA 19-9 kinetics helpful in predicting
survival in patients with advanced or metas-
tatic pancreatic cancer treated with gemcita-
bine and cisplatin? Onkologie 2003;26:462–7.
[20] Micke O, Bruns F, Schafer U, Kurowski R,
Horst E, Willich N. CA 19-9 in the therapy
monitoring and follow-up of locally advan-
ced cancer of the exocrine pancreas trea-
ted with radiochemotherapy. Anticancer Res
2003;23:835–40.
[21] Safi F, Schlosser W, Falkenreck S, Beger H.
Prognostic value of CA 19-9 serum course in
pancreatic cancer. Hepatogastroenterology
1998;45:253–9.
[22] Del Villano B, Brennan S, Brock P, et al.
Radioimmunometric assay for a monoclonal
antibody-defined tumor marker, CA 19-9.
Clin Chem 1983;29:549–52.
[23] Passerini R, Riggio D, Salvatici M, Zorzino
L, Radice D, Sandri M. Interchangeability
of measurements of CA 19-9 in serum with
four frequently used assays: an update. Clin
Chem Lab Med 2007;45:100–4.
[24] Passing H, Bablok. A new biometrical pro-
cedure for testing the equality of measure-
mentsfrom two different analytical methods.
Application of linear regression procedures
for method comparison studies in clinical
chemistry, Part I. J Clin Chem Clin Biochem
1983;21:709–20.
[25] La’ulu S, RobertsW. Performance characte-
ristics of five automated CA 19-9 assays. Am
J Clin Pathol 2007;127:436–40.
[26] Vestergaard EM, Hein HO, Meyer H, et al.
Reference values and biological variation
for tumor marker CA 19-9 in serum for
different Lewis and secretor genotypes and
evaluation of secretor and Lewis genoty-
ping in a Caucasian population. Clin Chem
1999;45:54–61.
[27] Fontana D, Della Beffa V, Fusca M, Loddo
F. Extralobar pulmonary sequestration sho-
wing high CA 19-19 levels. Minerva Chir
2007;62:39–42.
[18] Wu J, Olson J, Walker K. Tumor markers
CA 19-9 and CA 195 are also useful as
markers for cystic fibrosis. J Clin Lab Anal
1992;6:151–61.
[29] Fujita J, Dobashi N, Ohtsuki Y, et al. Detec-
tion of large molecular weight cytokeratin
8 as carrier protein of CA19-9 in non-
small-cell lung cancer cell lines. Br J Cancer
1999;81:769–73.
